Table 3A.
N evaluable | Patients with Infections N (%) | |
---|---|---|
1st 4 weeks | ||
Bacterial | 24 | 16 (67%) |
Gram negative | 1 | |
Gram positive | 13 | |
C. difficile | 2 | |
Viral | 8 (33%) | |
Polyoma | 3 | |
HSV | 4 | |
CMV | 1 | |
Fungal | 2 (8%) | |
Candida | 2 | |
5–8 weeks | ||
Bacterial | 20 | 5 (25%) |
Gram negative | 1 | |
Gram positive | 4 | |
Viral | 6 (30%) | |
HSV | 1 | |
CMV | 3 | |
EBV | 1 | |
Adenovirus | 1 | |
Fungal | 0 | |
9–12 weeks | ||
Bacterial | 20 | 6 (30%) |
Gram negative | 1 | |
Gram positive | 5 | |
Viral | 5 (25%) | |
HSV | 0 | |
CMV | 4 | |
EBV | 0 | |
Adenovirus | 1 | |
HHV-6 | 1 | |
Fungal | 2 (10%) | |
Candida | 2 | |
13–24 weeks | ||
Bacterial | 16 | 4 (25%) |
Gram negative | 0 | |
Gram positive | 4 | |
Viral | 3 (19%) | |
HSV | 0 | |
CMV | 2 | |
EBV | 0 | |
Adenovirus | 0 | |
HHV-6 | 1 | |
Fungal | 1 (6%) | |
Yeast, nos | 1 |
Grade 3 (requiring parenteral antimicrobial therapy; Grade 4 (life-threatening) and Grade 5 (fatal) infections reported over time.